NovaBay Pharmaceuticals has enrolled first patient in the BAYnovation Phase IIb study for adenoviral conjunctivitis.
The study will evaluate the company’s NVC-422, to treat adenoviral conjunctivitis, a highly contagious form of pink eye.
This global study is expected to enrol approximately 450 patients with confirmed adenoviral conjunctivitis at investigational sites in India, Brazil, and the US.
NovaBay chairman and chief executive officer Ron Najafi said, "We believe the FDA recognizes the need for a well-tolerated, topically administered therapy in this indication, as there is no current treatment for viral conjunctivitis."
The company has previously reported encouraging data from its Phase IIa clinical study, which suggested that NVC-422 may be efficacious in patients infected with adenoviral serotypes associated with epidemic keratoconjunctivitis.